# ๐Ÿฉธ Dialysis & Kidney Replacement Therapy ## ๐Ÿ“‹ Executive Summary Kidney replacement therapy represents the cornerstone of management for patients with end-stage renal disease, encompassing hemodialysis, peritoneal dialysis, and advanced modalities such as high-volume hemodiafiltration. The optimal timing for initiating renal replacement therapy has evolved from traditional GFR-based criteria toward **symptom-driven approaches**, supported by landmark evidence challenging early initiation strategies. Contemporary practice emphasizes individualized treatment selection based on patient factors, lifestyle considerations, and clinical presentation rather than arbitrary biochemical thresholds. Approximately **750,000 patients** in the United States currently receive chronic dialysis therapy, with projections indicating continued growth due to increasing prevalence of diabetes mellitus and hypertension. #### 750K US Dialysis Patients #### 3x/week Standard HD Schedule #### 24/7 vs 10/7 CAPD vs CCPD ## โš ๏ธ CRITICAL SAFETY ALERT: Post-Dialysis Potassium ### ๐Ÿšจ The Life-Threatening Trap #### โšก The Problem - Post-HD K+ appears artificially low due to rapid removal - K+ rebounds 0.5-1.0 mEq/L within 30-120 minutes - 95% of body K+ is intracellular - not reflected immediately - Equilibration takes hours, not minutes #### โ˜ ๏ธ The Danger - Supplementation + rebound = severe hyperkalemia - Risk of cardiac arrhythmias and arrest - Often delayed recognition until critically high levels - Well-documented case reports of preventable deaths #### โœ… The Solution - **NEVER** replace K+ based on immediate post-HD levels - Use pre-dialysis K+ for clinical decisions - If post-HD needed, wait 30-60 minutes minimum - Adjust dialysate K+ concentration instead #### ๐ŸŽฏ Clinical Pearl The post-dialysis K+ reflects extracellular depletion, not total body stores. True equilibration reveals the actual K+ status. This is not just a theoretical concern - it's a documented cause of preventable patient deaths. ## ๐Ÿ”‘ Key Clinical Insights #### ๐ŸŽฏ IDEAL Trial Revolution No survival benefit from early dialysis initiation. Start based on uremic symptoms, not GFR thresholds. Lead time bias explains previous observational data. #### ๐Ÿš€ HVHDF Survival Advantage High-volume hemodiafiltration with convection \>20L shows survival advantage. CONTRAST, Turkish HDF, and ESHOL trials demonstrate cardiovascular benefit. #### ๐Ÿ  Home Dialysis Excellence PD offers cardiovascular stability and lifestyle flexibility. Technique survival depends on patient selection and comprehensive training programs. ### โฐ Timing of Dialysis Initiation #### ๐Ÿ† IDEAL Trial (2010) - Landmark Evidence 828 patients randomized: Early (eGFR 10-14) vs Late (5-7 or symptoms). NO difference in survival, CV events, or QOL. Early group had longer exposure to complications without benefit. - **Historical GFR-Based:** Traditional eGFR 10-15 thresholds challenged - **Symptom-Based Criteria:** Uremic symptoms, fluid overload, metabolic acidosis - **Lead Time Bias:** Why observational studies were misleading - **Clinical Indicators:** Pericarditis, neuropathy, refractory HCOโ‚ƒ \<15 - **Meta-Analyses Confirmation:** Consistent absence of early benefit #### ๐ŸŽฏ Evidence-Based Approach Start dialysis when patients develop uremic symptoms, not when they reach arbitrary eGFR thresholds. Quality of life and cost considerations support symptom-driven initiation. ### ๐Ÿ”„ Hemodialysis Fundamentals #### โš™๏ธ Circuit Design & Blood Flow **Blood Flow:** 300-450 mL/min optimal range. **Dialysate:** 500-800 mL/min counter-current. **Access Flow:** Must exceed blood flow by 300-400 mL/min to prevent recirculation. - **Adequacy Targets:** KT/V \>1.2, URR \>65%, equilibrated KT/V considerations - **Treatment Time Primacy:** Most powerful predictor of adequacy and outcomes - **Blood Flow Optimization:** Curvilinear relationship with diminishing returns - **Dialyzer Selection:** Surface area, biocompatibility, high-flux benefits - **Pressure Monitoring:** Access recirculation detection (\>10-15% abnormal) #### ๐Ÿ“ˆ Optimization Key Treatment time is more important than blood flow rate for adequacy. Extended sessions allow better middle molecule clearance and improved cardiovascular tolerance. ### ๐Ÿ”„ Peritoneal Dialysis Mastery #### ๐Ÿงฌ Peritoneal Membrane Physiology 1-2 mยฒ peritoneal surface area. Transport heterogeneity classified by PET: High, high-average, low-average, low transporters. Transport status guides prescription optimization. - **PET Classification:** D/P creatinine at 4h determines transport status - **CAPD vs CCPD/APD:** 24/7 manual exchanges vs ~10/7 automated cycling - **Dialysate Solutions:** 1.5%, 2.5%, 4.25% glucose; icodextrin applications - **Adequacy Targets:** Weekly KT/V \>1.7, creatinine clearance \>50L/week - **Residual Function:** Critical for PD success, preserve at all costs - **Catheter Excellence:** Tenckhoff placement, break-in protocols ##### High Transporters D/P \>0.81\ Short dwells, CCPD preferred (~10/7) ##### Low Transporters D/P \<0.50\ Long dwells, CAPD suitable (24/7) ### ๐Ÿš€ High-Volume Hemodiafiltration #### ๐Ÿ† Survival Advantage Evidence **CONTRAST, Turkish HDF, ESHOL trials:** Volume-dependent survival benefit. Convection \>20-23L shows reduced overall and cardiovascular mortality. - **Convection Requirements:** \>20-25L per session for clinical benefit - **Technical Demands:** Ultrapure dialysate, high-flux membranes - **Middle Molecule Clearance:** Superior ฮฒ2-microglobulin, AGE removal - **Quality of Life:** Reduced interdialytic symptoms, faster recovery - **Access Requirements:** BF 350-450 mL/min consistently - **Cost-Effectiveness:** Higher initial costs offset by improved outcomes #### ๐Ÿ“Š Volume-Dependent Benefit Greatest survival improvements when convection volumes exceed 20L. Lower volumes show no consistent benefit - threshold effect for clinical improvement. ### ๐Ÿ”— Vascular Access Excellence #### ๐Ÿฅ‡ Fistula First Initiative AVF: Superior longevity, lowest infection rates, highest flow rates. 6-12 week maturation. AVG: Shorter maturation but higher complications. Catheters: Last resort due to infection and stenosis risks. - **Access Hierarchy:** Native fistula โ†’ graft โ†’ catheter preference - **Surveillance Protocols:** Monthly flow monitoring, stenosis detection - **Flow Requirements:** Access flow \>300-400 mL/min above prescribed BF - **Recirculation Monitoring:** \>10-15% indicates dysfunction - **Preemptive Intervention:** Early angioplasty prevents thrombosis - **CKD Stage 4-5 Planning:** Early nephrology referral essential #### ๐Ÿ“ˆ Access Impact on Outcomes Vascular access type is one of the strongest predictors of dialysis survival. Native fistulas offer the best long-term outcomes and lowest complication rates. ### ๐Ÿ“Š Adequacy & Monitoring #### ๐Ÿ“ KT/V Calculations **Single-Pool:** Assumes instant equilibration. **Equilibrated:** Accounts for urea rebound (10-15% lower). **Weekly Standard:** Normalizes different schedules for comparison. - **HD Targets:** Monthly KT/V \>1.2, URR \>65% - **PD Targets:** Weekly KT/V \>1.7, CrCl \>50L/week/1.73mยฒ - **Residual Function:** Monthly monitoring in PD, preservation critical - **Laboratory Surveillance:** Mineral metabolism, anemia, nutrition - **Quality Measures:** Patient-reported outcomes, hospitalization rates - **Technique Survival:** PD 15-20% annual failure, HD 90% survival ### ๐Ÿงฎ Advanced Dialysis Calculators #### Hemodialysis Adequacy Calculator Pre-Dialysis BUN (mg/dL): 60 Post-Dialysis BUN (mg/dL): 20 Treatment Time (hours): 4.0 Ultrafiltration Volume (L): 2.5 Body Weight (kg): 70 #### Single-Pool KT/V: 1.15 URR: 67% โœ… Adequate (Target \>65%) Equilibrated KT/V: ~1.02 (Est. 10-15% lower) Adequacy Status: โŒ Borderline (Target \>1.2) #### Peritoneal Dialysis Adequacy Calculator Peritoneal Weekly Urea Clearance (L): 50 Residual Renal Weekly KT/V: 0.5 Body Weight (kg): 70 Weekly Creatinine Clearance (L): 45 #### Total Weekly KT/V: 1.8 Peritoneal KT/V: 1.3 Creatinine Clearance: 45 L/week Adequacy Status: โœ… Adequate (KT/V \>1.7, CrCl target varies) #### High-Volume Hemodiafiltration Calculator Blood Flow Rate (mL/min): 400 Treatment Time (hours): 4.0 Filtration Fraction (%): 25 Hematocrit (%): 30 #### Convection Volume: 22.4 L Convection Rate: 5.6 L/hour Plasma Water Rate: 4.2 L/hour (corrected for Hct) Survival Benefit: โœ… Expected (\>20L threshold met) #### PET Classification Calculator Dialysate Creatinine at 4h (mg/dL): 8.5 Plasma Creatinine (mg/dL): 12.0 #### D/P Creatinine Ratio: 0.71 Transport Classification: High-Average Transporter Optimal Strategy: Moderate dwell times, flexible scheduling CAPD/APD: Either modality suitable ### ๐Ÿ”„ Comprehensive Dialysis Management Algorithm 1 **CKD Stage 4-5 Preparation:** Early nephrology referral (eGFR \<30), vascular access planning, modality education, symptom monitoring initiation 2 **Symptom Assessment:** Monitor for uremic complications: decreased appetite, nausea, altered mental status, fluid overload, pericarditis, neuropathy, metabolic acidosis (HCOโ‚ƒ \<15) 3 **Initiation Decision (Evidence-Based):** Start dialysis based on SYMPTOMS, not eGFR thresholds. IDEAL trial evidence: No survival benefit from early initiation 4 **Modality Selection:** PD if suitable home environment and motivated patient. HD if prefer in-center or PD contraindicated. Consider HVHDF if available and adequate access 5 **Prescription Optimization:** HD: KT/V \>1.2, treatment time prioritized. PD: Weekly KT/V \>1.7, preserve residual function. HVHDF: Convection \>20L target 6 **Adequacy Monitoring:** Monthly HD adequacy, monthly PD assessment with residual function. Access surveillance, laboratory monitoring (CKD-MBD, anemia) 7 **Complication Prevention:** Vascular access surveillance, mineral metabolism management, cardiovascular risk reduction, infection prevention protocols 8 **Critical Safety:** NEVER replace K+ based on immediate post-dialysis levels. Post-dialysis K+ measurements misleading due to rebound phenomenon ### ๐Ÿ’Ž Advanced Clinical Pearls #### ๐Ÿšจ Critical Safety Protocols - Post-dialysis K+ trap: 30-120 min rebound can be life-threatening - Disequilibrium syndrome: slow dialysis initiation in uremic patients - PD peritonitis: immediate empirical antibiotics prevent technique failure - Access dysfunction: \>15% recirculation warrants immediate evaluation #### ๐ŸŽฏ Optimization Strategies - Treatment time \> blood flow rate for adequate clearance - PD transport status guides prescription: high transporters need short dwells - Residual renal function preservation critical in PD patients - HVHDF requires \>20L convection volume for survival benefit #### ๐Ÿ“ˆ Outcome Predictors - Vascular access type strongest predictor of HD survival - Early nephrology referral (CKD stage 4) improves outcomes - Home dialysis modalities offer lifestyle and potential survival advantages - Symptom-based initiation equivalent outcomes to early GFR-based start #### ๐Ÿ”ฌ Technical Considerations - Ultrapure dialysate essential for HVHDF and online replacement fluid - High-flux membranes improve middle molecule clearance significantly - Icodextrin provides sustained UF in long PD dwells (\>8 hours) - Counter-current dialysate flow optimizes concentration gradients ### ๐Ÿ“š Evidence Base & Future Directions #### ๐Ÿ† Landmark Evidence - **IDEAL (2010):** No survival benefit from early dialysis initiation (eGFR 10-14 vs 5-7) - **CONTRAST (2013):** Online HDF survival advantage with high convection volumes - **Turkish HDF (2013):** Confirmed survival benefit of high-volume hemodiafiltration - **ESHOL (2013):** Post-dilution online HDF reduced mortality risk - **NECOSAD:** PD vs HD equivalent survival in comparable patients #### ๐Ÿ“‹ Current Guidelines (2024) - **KDOQI 2015 (Updated):** Symptom-based dialysis initiation recommendations - **ISPD 2022:** Updated peritonitis prevention and catheter care guidelines - **ASN Home Dialysis Initiative:** Promotion of home-based therapies - **DOPPS Analysis:** Outcomes and practice pattern insights - **Vascular Access Guidelines:** Fistula first, surveillance protocols #### ๐Ÿš€ Future Innovations **Portable Devices:** Wearable artificial kidneys, home-friendly technology **Enhanced Biocompatibility:** Next-generation membrane materials **AI Optimization:** Machine learning for prescription personalization **Precision Medicine:** Genomic-guided therapy selection ### ๐Ÿ“‹ Dialysis Prescription & Complications Comprehensive guide to dialysis prescription optimization, intradialytic complications, and troubleshooting strategies ### ๐Ÿ”— Vascular Access Selection โ€” Rethinking "Fistula First" Why the fistula-first survival benefit is largely selection bias, what the ACCESS-HD trial showed, and the ESKD Life-Plan framework for the older starter ## ๐Ÿ“š Sources 1. **Cooper BA, Branley P, Bulfone L, et al; IDEAL Study.** A randomized, controlled trial of early versus late initiation of dialysis. *N Engl J Med.* 2010;363(7):609-619. [PMID: 20581422](https://pubmed.ncbi.nlm.nih.gov/20581422/). *โ€” IDEAL trial: early (eGFR 10-14) vs late (5-7) dialysis initiation; no survival benefit, mostly symptom-driven start. N=828.* 2. **Grooteman MP, van den Dorpel MA, Bots ML, et al; CONTRAST Investigators.** Effect of online hemodiafiltration on all-cause mortality and cardiovascular outcomes. *J Am Soc Nephrol.* 2012;23(6):1087-1096. [PMID: 22539829](https://pubmed.ncbi.nlm.nih.gov/22539829/). *โ€” CONTRAST: HDF vs HD; no significant mortality difference overall.* 3. **Maduell F, Moreso F, Pons M, et al; ESHOL Study Group.** High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients. *J Am Soc Nephrol.* 2013;24(3):487-497. [PMID: 23411788](https://pubmed.ncbi.nlm.nih.gov/23411788/). *โ€” ESHOL: post-dilution online HDF vs HD; significant 30% all-cause mortality reduction at convection volumes \>20L. Foundational HDF survival evidence.* 4. **National Kidney Foundation.** KDOQI Clinical Practice Guideline for Hemodialysis Adequacy: 2015 Update. *Am J Kidney Dis.* 2015;66(5):884-930. [PMID: 26498416](https://pubmed.ncbi.nlm.nih.gov/26498416/). *โ€” KDOQI 2015 update: KT/V targets, frequency recommendations, vascular access.* 5. **Li PK, Szeto CC, Piraino B, et al.** ISPD Peritonitis Recommendations: 2022 Update on Prevention and Treatment. *Perit Dial Int.* 2022;42(2):110-153. [PMID: 35264029](https://pubmed.ncbi.nlm.nih.gov/35264029/). *โ€” ISPD 2022 peritonitis prevention and treatment guideline; cited in PD section.* ๐Ÿ“š For Educational Purposes Only - University of Dubuque PA Program ยฉ 2025 Andrew Bland MD - All Rights Reserved --- [Website version](https://urinenephrology.org/2025_UDPA_Lectures_Live/dialysis/index.html) ยท Markdown synchronized October 3, 2026.